Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Sangamo Therapeutics (SGMO) over the last 16 years, with Q3 2025 value amounting to $2.1 million.

  • Sangamo Therapeutics' Share-based Compensation fell 3583.71% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year decrease of 3271.08%. This contributed to the annual value of $12.4 million for FY2024, which is 5474.91% down from last year.
  • According to the latest figures from Q3 2025, Sangamo Therapeutics' Share-based Compensation is $2.1 million, which was down 3583.71% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Sangamo Therapeutics' Share-based Compensation ranged from a high of $9.5 million in Q2 2021 and a low of $2.1 million during Q3 2025
  • Moreover, its 5-year median value for Share-based Compensation was $6.8 million (2023), whereas its average is $5.9 million.
  • As far as peak fluctuations go, Sangamo Therapeutics' Share-based Compensation soared by 4019.81% in 2021, and later plummeted by 6714.99% in 2024.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Share-based Compensation stood at $8.1 million in 2021, then grew by 2.13% to $8.2 million in 2022, then decreased by 25.96% to $6.1 million in 2023, then crashed by 46.24% to $3.3 million in 2024, then tumbled by 35.21% to $2.1 million in 2025.
  • Its Share-based Compensation stands at $2.1 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.6 million for Q1 2025.